China Medical System （00867）Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer’s Type
As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...
New dementia tool predicts when symptoms will start: ‘Would you want to know?’
Nearly 7 million Americans have been diagnosed with dementia, which slowly erodes memory, thinking skills and the ability to ...
Florey Dementia Index: This online tool predicts age of onset for early Alzheimer’s disease
A simple digital health tool developed by Australian researchers could soon help predict the age of onset for early Alzheimer ...
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China
Alpha Cognition and China Medical System sign a $44M licensing deal for Zunveyl. ALPHA-1062 preclinical data shows benefits ...
Genetic changes in brain cells link aging and Alzheimer's
Genetic differences that contribute to how long a person will live and their risk of Alzheimer's disease have been identified ...
Hosted on MSN2d
Breakthrough drugs herald ‘new era’ in battle against dementia, experts predict
Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...
UK scientists uncover startling new link between HRT and Alzheimer's
Several recent studies have suggested HRT is a risk factor in various conditions, notably Alzheimer's - now UK boffins have ...
Five monumental Alzheimer’s discoveries scientists made in 2024
With an estimated 6.9 million Americans aged 65 and older currently living with Alzheimer’s disease, the road to a cure seems ...
Fox News14d
5 major Alzheimer’s discoveries scientists made in 2024
With an estimated 6.9 million Americans aged 65 and older currently living with Alzheimer's disease, the road to a cure seems ...
Miracle Alzheimer's drug which could slow down the disease is being considered for use on the NHS - giving hope to millions of people
Officials are assessing whether hydromethylthionine mesylate (HMTM) shows sufficient promise to be given the green light for ...
Axsome to seek approval for Alzheimer's-related agitation drug despite mixed data
Axsome Therapeutics said on Monday its experimental treatment for the Alzheimer's disease-related agitation met the main goal of a late-stage trial.
Why Alzheimer’s Scientists Are Re-thinking the Amyloid Hypothesis
For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...